MARLBOROUGH, Mass., Feb. 18, 2016 /PRNewswire/ -- Hologic Inc. (Nasdaq: HOLX) announced today that a new longitudinal study published online in advance of print in JAMA Oncology reports that women screened for breast cancer over multiple years using Hologic's Genius 3D MAMMOGRAPHY™ exams benefited from a significant drop in costly and stressful recalls.1
The findings published in JAMA Oncology provide longitudinal evidence that the benefits of 3D MAMMOGRAPHY™ exams – fewer women called back, more cancer cases found in recalled patients, and fewer cancers diagnosed between regular scheduled screenings – can be sustained and even improved over time with consecutive use. JAMA Oncology is a monthly peer-reviewed medical journal published by the American Medical Association.
Emily F. Conant, MD, senior author, and her co-researchers analyzed screening mammography metrics for 23,958 women at the University of Pennsylvania over a four-year period. Differences in screening outcomes were assessed for women screened with standard digital mammography, women screened with 3D MAMMOGRAPHY™ exams, and women screened with 3D MAMMOGRAPHY™ exams over multiple years. The authors conclude that sustained, and even improved, performance is possible over time when 3D MAMMOGRAPHY™ exams are used in population-based screening.
"The new JAMA Oncology study is a significant addition to the already substantial body of research showing that Genius™ 3D MAMMOGRAPHY™ exams increase invasive cancer detection and reduce the number of women recalled for additional imaging," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "This new study demonstrates that the benefits of 3D MAMMOGRAPHY™ are sustainable, and further supports the importance and need for this life-saving technology."
Hologic's Genius™ 3D MAMMOGRAPHY™ exams have been available in the United States since February 2011. In 2015 an estimated 7.5 million women in the U.S. benefited from Genius™ 3D MAMMOGRAPHY™ exams. Additional information, as well as a locator to find imaging sites offering the exams, can be found at http://mygenius3d.com/
Conant is a paid scientific advisor and lecturer for Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, Genius, and the Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic mammography systems. There can be no assurance the systems will achieve the benefits described here, or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that the systems will achieve any expected level of sales or market share. Hologic expressly disclaims any obligation to release publicly any updates to the data or statements presented here to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.
1 Elizabeth S. McDonald, MD, PhD; Andrew Oustimov, MPH; Susan P. Weinstein, MD; Marie B. Synnestvedt, PhD; Mitchell Schnall, MD, PhD, and Emily F. Conant, MD. Effectiveness of Digital Breast Tomosynthesis Compared with Digital Mammography. JAMA Oncol. 2016;2(6):1-7. Doi:10:10.1001/jamoncol. 2015.5536.
SOURCE Hologic, Inc.